Bioworkshops
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $50M
Overview
A professional biologics CDMO in China offering end-to-end development and manufacturing services for complex antibody therapeutics.
OncologyImmunology
Technology Platform
Integrated biologics CDMO platform featuring high-expression stable cell line development for complex antibodies (mAbs, bsAbs, trispecifics) and end-to-end process development, analytics, and cGMP manufacturing using single-use bioreactor technology.
Opportunities
Growth is driven by increasing global demand for biologics CDMO services, particularly for complex antibody formats, and Bioworkshops' strategic position in China to serve both domestic and international biopharma companies seeking cost-effective, high-quality manufacturing.
Risk Factors
Key risks include intense competition from established global CDMOs, potential regulatory complexities in cross-border client projects, and the capital-intensive nature of maintaining and expanding state-of-the-art manufacturing facilities.
Competitive Landscape
Competes with global CDMOs like Lonza, Samsung Biologics, and WuXi Biologics, as well as regional players. Differentiation is based on specialized expertise in complex antibodies, integrated 'one-stop' services in China, and a strong track record in global regulatory compliance (FDA, EMA, NMPA).